Study register · detail
Clear benefit
GRADE
High
67 citations
SampleMeta-Analyse
ControlNo cannabis use / no tobacco use
EndpointAge at first illness
Blindingunklar
DesignMeta-Analyse
Key finding
Cannabis use is robustly associated with a 32 months earlier onset of psychosis, independent of tobacco use and other confounders examined.
Summary
Meta-analysis on the association between cannabis use and earlier first onset of psychosis; cannabis users developed psychosis on average 32 months earlier than non-users (SMD=-0,399, 95% CI -0,493 to -0,306, p<0,001); finding robust against confounders (tobacco use, sex, diagnostic criteria); no corresponding effect for tobacco alone (SMD=0,002, p=0,974).
P
PopulationPersons with schizophrenia and other psychoses, divided into cannabis users vs. non-users as well as tobacco smokers vs. non-smokers
I
InterventionCannabis use (as exposure)
C
ControlNo cannabis use / no tobacco use
O
OutcomeAge at onset of illness in cannabis users 32 months earlier than in non-users (SMD=-0.399, 95%-CI -0.493 to -0.306, p<0.001); no significant difference for tobacco smokers vs. non-smokers (SMD=0.002, p=0.974)
Confidence in the evidence
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size
—
Blinding
—
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
A recent meta-analysis showed that the mean age of onset of psychosis among cannabis users was almost three years earlier than that of non-cannabis users. However, because cannabis users usually smoke tobacco, the use of tobacco might independently contribute to the earlier onset of psychosis. We aimed to use meta-analysis to compare the extent to which cannabis and tobacco use are each associated with an earlier age at onset of schizophrenia and other psychoses. We also examined other factors that might have contributed to the finding of an earlier age of onset among cannabis users, including the proportion of males in the samples, the diagnostic inclusion criteria and aspects of study quality. The electronic databases MEDLINE, EMBASE, PsycINFO and ISI Web of Science, were searched for English-language peer-reviewed publications that reported age at onset of schizophrenia and other psychoses separately for cannabis users and non-users, or for tobaccosmokers and non-smokers. Meta-analysis showed that the age at onset of psychosis for cannabis users was 32 months earlier than for cannabis non-users (SMD=- 0.399, 95%CI -0.493 - -0.306, z=-8.34, p < 0.001), and was two weeks later in tobacco smokers compared with non-smokers (SMD=0.002, 95%CI -0.094 - 0.097, z=0.03, p=0.974). The main results were not affected by subgroup analyses examining studies of a single sex, the methods for making psychiatric diagnoses and measures of study quality. The results suggest that the association between cannabis use and earlier onset of psychosis is robust and is not the result either of tobacco smoking by cannabis using patients or the other potentially confounding factors we examined. This supports the hypothesis that, in some patients, cannabis use plays a causal role in the development of schizophrenia and raises the possibility of treating schizophrenia with new pharmacological treatments that have an affinity for endo-cannabinoid receptors.
The impediment to action advances action.